Shares of clinical-stage company Bellerophon Therapeutics (NASDAQ:BLPH) are soaring high today after the U.S. Food and Drug Administration (FDA) agreed to a reduction in the size of BLPH’s Phase 3 study of INOpulse for treating fibrotic interstitial lung disease (fiLD).
The data monitoring committee of the study supported lowering the study size to 140 from 300 and the change does not affect the trial’s principal objective or endpoints.
The company expects to complete enrolment in Q1 2023 with top-line data expected in Q3 2023.
Is BLPH a Good Stock to Buy?
Impressively, the Street has a Moderate Buy consensus rating on the stock alongside an average price target of $30 which implies a massive 2358.81% potential upside in the stock.
Read full Disclosure
